Sponsor

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) appears in 3 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials3
Recruiting shown3
Roles1
SourceClinicalTrials.gov
Advertisement

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
pembrolizumab2
bevacizumab1
cetuximab1
fulvestrant1
gemcitabine1
paclitaxel protein-bound1
pemetrexed1
ribociclib1

Sponsor roles

lead sponsor3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.